
Democratizing health by creating vaccines for chronic diseases. 💛 #DemocratizeHealth
Everywhere
Joined July 2020
- Tweets517
- Following361
- Followers2.4K
- Likes273
Vaxxinity retweeted
The new research is early, but it's a hopeful advance for patients with the neurological condition
time.com/6883054/parkinsons-…
Vaxxinity retweeted
Vaxxinity published data from an early-stage clinical trial showing that its investigative immunotherapy, UB-312, could improve movement in Parkinson’s disease and protect against pathological alpha-synuclein.
#parkinsons #biospace
hubs.li/Q02CGTgP0
Vaxxinity retweeted
News from @vaxxinity and @UF on a #collaboration to advance #vaccine development for #neurodegenerative diseases like #parkinsons and #alzheimers.
#vaccinenation #vaccines #disease #florida
vaccinenation.org/therapeuti…
Vaxxinity retweeted
Under the agreement, @uf scientists will conduct preclinical studies exploring effects of vaccines for neurodegenerative diseases. See more: buff.ly/42zQokj
#parkinsons #parkinsonsdisease #parkinsonsresearch #parkinsonstreatment
Vaxxinity retweeted
Vaxxinity Inc. will work with the University of Central Florida in Orlando to develop special new vaccines for astronauts that aim to prevent a common problem created during space exploration. Click for the details. bizjournals.com/orlando/news…
Vaxxinity retweeted
Could space travel research deliver a frailty vaccine?
@vaxxinity and UCF collaborate on muscle and bone wasting immunotherapies to benefit both space exploration and human longevity.
@NotLouReese #longevity #space #research #vaccine
longevity.technology/news/co…
Vaxxinity retweeted
Researchers return to Alzheimer's vaccines, buoyed by recent drug success reut.rs/3R3MQ5M
Vaxxinity retweeted
Meet our Hidden Hero Rob Townley who work with some of our most complex and high risk projects at @Maersk👊Learn more about how Rob helps bring our #purpose to life⭐
👉Watch the full video: youtu.be/i0KeZuW6wKw
#Maersk #HiddenHero #alltheway #Career
Vaxxinity retweeted
Jean-Cosme Dodart (@vaxxinity) discussed recently published trial findings on a novel vaccine that targets Alzheimer's disease and triggers the production of antibodies against toxic amyloid-ß peptides.
Watch here 👇 ow.ly/HBLP50PAV24
Vaxxinity retweeted
#ICYMI: Phase 1 trial results investigating UB-312 (@vaxxinity) revealed target engagement of aggregated alpha-synuclein in cerebrospinal fluid of patients with Parkinson disease.
Read more: ow.ly/21hk50PusiP
Vaxxinity retweeted
Treatment with an investigational anti-#amyloid therapeutic for adults with mild #AD was safe, efficacious and demonstrated a significant immune response up to 78 weeks, per a @Vaxxinity study published in @eBioMedicine. bit.ly/3qqCAtU
Vaxxinity retweeted
Vaxxinity - Expansively Disrupting Medicine
Read more: bit.ly/3OnDFuF
#ChronicDiseaseVaccines
Vaxxinity retweeted
Did you miss last week's fireside chat on vaccines for #dementia?
If so, you can find the inspiring & informative 30-minute conversation with ADI's @WeidnerWendy, @AC_Immune_SA's Andrea Pfeifer & Mei Mei Hu of @vaxxinity, on our YouTube channel. youtu.be/h7A93G0HVxU
Vaxxinity retweeted
Positive steps from @vaxxinity against #parkinsonsdisease as they continue to see results from their #vaccine UB-312.
#vaccinenation #vaccines #parkinsons #disease #vaxxinity
vaccinenation.org/therapeuti…
Vaxxinity retweeted
Immune response triggered by UB-312 was seen in patients' CSF to target and engage alpha-synuclein clumps and slow their toxic buildup. buff.ly/44CI3Ni
#parkinsonssymptoms #parkinsonsdiseaseresearch #parkinsonsdisease #livingwithparkinsons
Vaxxinity retweeted
Positive #parkinsons vaccine results from @vaxxinity released show progress on #asyn targeting treatment.
#vaccinenation #vaccine #parkinsonsdisease #vaxxinity
vaccinenation.org/therapeuti…
Vaxxinity retweeted
Vaxxinity reports positive #Parkinsonsvaccine trial results
@vaxxinity has announced positive results from Part B of its Phase 1 #clinicaltrial for UB-312, an investigational vaccine for #Parkinsonsdisease.
#biotech #investment #longevity
longevity.technology/news/va…
Vaxxinity retweeted
In recent news, Vaxxinity announced positive results from Part B of its phase 1 placebo-controlled, double-blind clinical trial of UB-312, an investigational vaccine for Parkinson's, with the vaccine meeting its primary objectives.
ow.ly/C3Bl50OWFWG
Vaxxinity retweeted
Results from a Phase 1 trial testing experimental vaccine UB-312 for Parkinson’s disease are expected this summer, Vaxxinity announced. buff.ly/3Ocbj7U
#parkinsonsdiseaseresearch #parkinsonsdisease #livingwithparkinsons
Vaxxinity retweeted
New ways to target pathologic tau focus on intracellular tau, vaccines, and multivalent molecules that attack several types of fibril. #alzheimersdisease ow.ly/YgGo50Ofh39


















